研究者情報   
   検索ページ


    (最終更新日:2017-05-30 15:09:37)
  ツダ タカシ   TSUDA TAKASHI
  津田享志
   所属   医学部医学科 臨床腫瘍学
   職種   講師
■ 学術雑誌
1. 原著  Identification of FGFR3-TACC3 fusion in esophageal cancer 2017/02
2. 原著  Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison. 2016/04
3. 原著  Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/04
4. 原著  Predictability of the anti-tumor efficacy of cetuximab plus irinotecan based on skin rash severity according to observation period in patients with metastatic colorectal cancer after fluorouracil, irinotecan, and oxaliplatin failure 2015/01
5. 症例報告  大腸癌化学療法中に食道胃静脈瘤破裂をきたした2症例 2014/12
全件表示(25件)
■ 学会発表
1. "Randomized phase II study of panitumumab (Pmab) plus irinotecan (CPT-11) versus cetuximab (Cmab) plus CPT-11 in patients
with KRAS wild-type (WT) metastatic colorectal cancer (mCRC) following treatment with fluoropyrimidine, CPT-11, and
oxaliplatin (L-OHP) chemotherapy: WJOG6510G."  2017/01
2. Predictability of survival outcome by early tumor shrinkage (ETS) at 8 weeks with cutoff value of 20% in metastatic colorectal cancer (mCRC) patients treated with mFOLFOX6 plus bevacizumab (bev) or FOLFIRI plus bev as first-line chemotherapy (1st-CTx): validation in the phase III WJOG4407G trial  2017/01
3. 当院のIO副作用対策チームの取り組み (シンポジウム・ワークショップ・パネルディスカッション等) 2016/07/29
4. 切除不能進行・再発大腸癌に対するサルベージライン化学療法(regorafenib, TAS102)の後方視的検討 (口頭発表,一般) 2016/07/28
5. 聖マリアンナ医科大学病院におけるシスプラチンによる腎障害の実態と軽減対策の効果  2016/03
全件表示(32件)